Own your ow legal marijuana business | Your guide to making money in the multi-billion dollar marijuana industry |
Major Studies of Drugs and Drug Policy | ||||
Canadian Senate Special Committee on Illegal Drugs | ||||
Volume I - General Orientation |
|
Chapter
9
Use of marijuana for
therapeutic Purposes
There has been renewed interest in the issue of the use of marijuana for
therapeutic purposes in recent years, particularly in Canada. In the wake of an
Ontario Court of Appeal ruling which found the provisions of the Controlled Drugs and Substances Act to
be unconstitutional pertaining to the therapeutic use of marijuana, the federal
Health Minister made new regulations in July 2001 that give people with
specified medical problems access to marijuana under certain conditions. Later
that same year, an international conference on medicinal cannabis held in The
Hague, Netherlands, drew delegates from Canada and several other Western
countries.[1][1] Earlier, in 1999, the National Institute
of Medicine in the United States published an assessment of the science base of
marijuana and medicine.[2][2] However, the scientific community –
the medical community in particular – is divided on the real therapeutic
effectiveness of marijuana. Some are quick to say that opening the door to
medical marijuana would be a step toward outright legalization of the substance.
Witness the following two quotes, the first of which is from a former director
of the National Institute on Drug Abuse (NIDA) in the United States: It
is primarily the political muscle of the marijuana legalization proponents that
today creates the motivation to do additional research on marijuana smoke. […]
There is one explanation for the strident insistence of marijuana legalization
proponents that only smoked marijuana will do as ‘medicine’. They appear to be
determined to have sick medical patients smoking marijuana in the public eye.
They want that outcome because that act legitimizes the use of marijuana by
changing the common public perception of marijuana from a harmful drug to a
useful medicine. [3][3] Although
many who champion medical marijuana use do so on compassionate grounds, with
the firm conviction that smoked marijuana provides benefits unavailable by
other means, much support comes from those who advocate the liberalization of
drug policy and the decriminalization of drug use. [4][4] It is true, as Professor Mark Ware
pointed out in his testimony before the Committee, that in the current legal
and political context, it is difficult to conduct studies and, more
importantly, do so without being influenced by the heated debate over marijuana. Let
us look at the effect that current drug policy has had on our understanding of
cannabis. All our data on the health effects of cannabis have been collected
under a paradigm of prohibition. This may seem self-evident but it constitutes
an important source of bias. In examining the health effects of cannabis, an
estimate of the use of cannabis in the healthy population is important. […]
Surveys of illicit drug use are notorious for poor response rates. It hampers
our ability to draw conclusions on what cannabis does, if we don’t really know
who is doing it. It is important to estimate the size of the bias, and the
effect it has had, and good research will always try to minimize it. However,
in my experience of critically reviewing the literature on cannabis effects on
health, examples exist where important estimates of risk are based on studies
which have inappropriate control selection. […] The question therefore changes
from ‘how has cannabis policy affected health?’ and becomes ‘has cannabis
policy affected our understanding of the health effects of cannabis?’ [5][5] It is also true that the issue of medicinal
marijuana challenges us on the very concept of modern medicine and its links
with the pharmaceuticals industry, since research on cannabinoids has already
led to the development of synthetic THC compounds. Drug companies are known to
have played a major role in international negotiations leading to the adoption
of the first international conventions on the control of psychoactive
substances.[6][6] Moreover, the marijuana plant itself,
because it cannot be patented, is of no interest to major pharmaceutical
research groups. Beyond the scientific “proof” that
marijuana is effective and the prospect of physicians prescribing marijuana
with sufficient confidence, many people believe, based on personal experience,
that marijuana has a direct impact in terms of improving their well-being with
minimum adverse effects. That view is what led to the creation of “compassion
clubs”, organizations that distribute marijuana to growing numbers of clients.
One of the questions this raises is how much evidence is needed before people
can be allowed to freely use marijuana to relieve a medical condition. Indeed,
do we have to think of marijuana in strictly medical terms? We
saw in Chapter 7 that the long-term effects of using marijuana, even on a
regular basis, are limited and that even the most serious effects, such as lung
cancer, have yet to be clearly demonstrated. We also saw that the adverse
effects of prolonged use on cognitive function are more prevalent in people who
are already vulnerable because of their young age when they started using, for
example, or their personal condition (for example, psychotic predispositions).
We also saw that, even assuming some tolerance and a certain level of
psychological dependency, those effects are minor, the signs of withdrawal
minor, and treatment shorter and less often necessary than for other drugs. To
a degree, it appears that the psychoactive properties of marijuana, which some
see coupled with rejection of society, others with a weak personality and still
others with immoral behaviour, make the substance suspect, whether in medical
or non-medical applications. In that sense, the issue of medical
marijuana is not so much a question of legalization through the back door as it
is a question of open examination of each person’s underlying conception of the
“drug”. In a way, it is a prime opportunity to explore our preconceptions and
prejudices. Stating, as we did in Chapters 6 and 7, that the psychological,
physiological or social effects of marijuana use are by all indications
relatively benign says nothing about the therapeutic benefits of the plant in
the same way that medical uses of the poppy say nothing about the individual or
social harm that can be caused by heroin. Dr. Kalant echoed this view: The
separation of the control methods between medical and non-medical use is
generally clearly understood. Both heroin and cocaine have limited but
recognized medical uses. […] Yet, nobody argues that, because these drugs have
some limited medical use, that they should therefore be legalized for
non-medical use. […] Cannabis is perhaps the one exception in which possible
medical uses are often claimed by some proponents of legalization of cannabis
as a justification for legalization for non-medical use. This to me seems quite
irrational. There is no logical reason why having a medical use should be any
argument at all, either for or against, availability for non-medical use. [7][7] However, as Dr. Ware reiterated, “the safety of cannabis in humans has been
extensively studied, thanks in part to the massive Western cohort of ‘healthy
human volunteers’ of the last 40 years. Cannabis may have undergone the
most extensive and unorthodox Phase I clinical trials of any drug in history.”[8][8] While it is true that research protocols
to allow medical use of a substance are and must remain rigorous, there is no
clear boundary between the two areas of research. This was illustrated to some
extent in the review in Chapter 7 of studies on the effects and
consequences of marijuana. Indeed, the opposite approach struck us as more
common, where, based on the presumed harmful effects of marijuana on
psychological and physical health, the therapeutic usefulness of marijuana
becomes at least suspect. We take as an example the position of the Canadian
Medical Association. In
his testimony before the Commission, current CMA president
Dr. Henry Haddad said: While
our understanding of all the possible long-term health effects that prolong
Canada's use is still evolving, what we do know is troubling. The health risks
range from acute effects such as anxiety, dysphoria, or the feeling of being
ill; cognitive impairment to the chronic effects such as bronchitis, emphysema
and cancer. Canada's youth have also been subject to pulmonary damage
comparable to that produced by tobacco use but the effects are much more acute
and rapid. Evidence suggests that smoking two or three cannabis cigarettes a
day has the same health effect as smoking 20 cigarettes a day. Therefore, the
potential long-term health effects of cannabis use could be quite severe. The
CMA's concerns regarding the impact of cannabis are in part why we are opposed
to the federal government's current medical marijuana access regulations. In
our May 7, 2001, letter to the Minister of Health, the CMA noted ‘lack of
credible information on the risks and benefits of medical marijuana.’ During
discussions on the government's medical marijuana regulations, we highlighted
the health concerns and research that indicates that “marijuana is an addictive
substance that is known to have psychoactive effects and in its smoke form is
particularly harmful to health.'' We
have concluded that while benefits of medical marijuana are unknown, the health
risks are real. Therefore, it would be inappropriate for physicians to
prescribe marijuana to their patients, a position that was supported by the
Canadian Medical Association. […] The
CMA is concerned that this debate concerning decriminalization and the medical
marijuana issue has, to some extent, legitimized its use for recreational
purposes. It is important that our message to you regarding decriminalization
be clear and understood. Decriminalization must be tied to a national drug
strategy that promotes awareness and prevention and provides for comprehensive
treatment in addition to research and monitoring of the program. […] The
CMA believes that any changes regarding illegal drug policy should be gradual.
Like any other public health issue, education and awareness of the potential
harms associated with cannabis and other illegal drug use is critical to
reducing drug usage. [9][9] If we were to succeed in showing
that the effects are not as bad as had been thought, would it change in any way
the issues related to medical use of marijuana? The acute effects identified by
the CMA are possible but relatively rare and often the product of personal
predispositions, context or a particular crop of marijuana. In fact, the
primary acute reactions, the reactions documented by most of the research, are
pleasant and help the user relax. If we were to convince the medical
association that marijuana is not particularly addictive and that even where it
is, the effects are relatively benign, would that clear the way for medical use
of marijuana? Aside from the fact that marijuana is only tenuously linked to
“drug addiction”, there is by no means consensus in the scientific community on
the very notion of drug addiction, viewed primarily as a disease. The question lies elsewhere – in two
places, in fact. First, knowledge of the potentially harmful effects of
marijuana says nothing about the qualities of the plant as a medicine. To be
sure, knowledge of the secondary effects of drugs, including their addictive
potential, is essential to the pharmacopoeia. However, those substances must
first be established as drugs, particularly in terms of effectiveness and
reliability. Second, the whole issue is broached as if resistance to medical
use of marijuana were based not so much on the absence of medical knowledge per se – which is the case to some
extent, as we will see later in this chapter – as on the link between marijuana
and drug addiction. From that perspective, the issue is quickly resolved: in
keeping with the medical maxim “first do
no harm”, a physician will not prescribe a treatment the effects of which
could lead to an illness at least as serious as the illness being treated in
the first place. If marijuana is listed as an illegal drug, banned in some
contexts because of its harmful effects and capable of leading to drug addiction,
what compelling arguments could be put forward to “save” medical marijuana? But none of that should matter to
physicians or scientists. It is not a question of defending general public
policy on marijuana or even all illegal drugs. It is not a question of sending
a symbolic message about “drugs”. It is not a question of being afraid that
young people will use marijuana if it is approved as a medicine. The question –
the only question – for physicians is whether, to what extent and in what
circumstances, marijuana serves a therapeutic purpose. Physicians would have to
determine whether people with certain diseases would benefit from marijuana use
and weigh the side effects against the benefits. If they decide the patient
should use marijuana, they then have to consider how he or she might get it.
The issue of deciding whether cannabis has therapeutic benefits is obviously
clouded by the current legal context on cannabis. This may be inevitable, but
those who take public positions on cannabis for therapeutic purposes should say
so. The rest of this chapter is devoted
to the history of the use of marijuana for therapeutic purposes and the status
of contemporary knowledge of marijuana and synthetic cannabinoids. We then give
a brief account of compassion clubs and other organizations that supply
marijuana for therapeutic use, as well as various public policy regimes. We
conclude with our views on medical use of marijuana. In a later chapter, we
discuss which public policy regime would be most appropriate given the status
of medical use of marijuana. [1][1]
International Conference on
Medicinal Cannabis, November 22-23, 2001, The Hague, Netherlands. [2][2] Joy, J.E., S.J. Watson and J.A.
Benson (1999) (eds.), Marijuana and
Medicine: Assessing the Science Base. Washington, D.C.: National Academy
Press. [3][3]
DuPont, R.L. (1999), “Examining the Debate on the Use of Medical
Marijuana”, Proceedings of the
Association of American Physicians, Volume 111, No. 2, page 169. [4][4]
Rosenthal, M.S., and H.D. Kleber (1999), “Making Sense of Medical
Marijuana”, Proceedings of the
Association of American Physicians, Volume 111, No. 2, page 159. [5][5]
Dr. Mark Ware, Assistant Professor of Family Medicine and Anesthesia,
McGill University, testimony before the Special Senate Committee on Illegal
Drugs, Senate of Canada, May 31, 2002. [6][6]
See in particular the study by W.B. McAllistair, Drug Diplomacy in the 20th Century. This point will be
discussed later in chapter 19. [7][7]
Dr. Harold Kalant, Professor Emeritus at the University of Toronto,
testimony before the Special Senate Committee on Illegal Drugs, Senate of
Canada, first session of the thirty-seventh Parliament, June 11, 2001, Issue 4,
pages 70-71. [8][8]
Dr. Mark Ware, op.cit. [9][9]
Dr. Henry Haddad, President, Canadian Medical Association, testimony
before the Special Senate Committee on Illegal Drugs, Senate of Canada, first
session of the thirty-seventh Parliament, March 11, 2002,
Issue 14, pages 52-53 and 54-55. |